SG11202009735QA - Bcl6 inhibitors - Google Patents
Bcl6 inhibitorsInfo
- Publication number
- SG11202009735QA SG11202009735QA SG11202009735QA SG11202009735QA SG11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA SG 11202009735Q A SG11202009735Q A SG 11202009735QA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl6 inhibitors
- bcl6
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
| GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
| PCT/GB2019/051058 WO2019197842A1 (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009735QA true SG11202009735QA (en) | 2020-10-29 |
Family
ID=66240166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009735QA SG11202009735QA (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11512095B2 (en) |
| EP (2) | EP3774817B1 (en) |
| JP (2) | JP7493454B2 (en) |
| KR (1) | KR20200144109A (en) |
| CN (1) | CN112334475B (en) |
| AU (2) | AU2019253510B2 (en) |
| BR (1) | BR112020020832A2 (en) |
| CA (1) | CA3095371A1 (en) |
| DK (1) | DK3774817T3 (en) |
| ES (1) | ES2939776T3 (en) |
| HR (1) | HRP20230120T1 (en) |
| IL (2) | IL296734A (en) |
| MX (2) | MX2020010805A (en) |
| PT (1) | PT3774817T (en) |
| SG (1) | SG11202009735QA (en) |
| WO (1) | WO2019197842A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009735QA (en) * | 2018-04-13 | 2020-10-29 | Cancer Research Tech Ltd | Bcl6 inhibitors |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| EP4045496A1 (en) * | 2019-10-17 | 2022-08-24 | Arvinas Operations, Inc. | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| BR112023021265A2 (en) | 2021-04-16 | 2024-02-27 | Arvinas Operations Inc | BCL6 PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE |
| US20240287091A1 (en) | 2022-06-06 | 2024-08-29 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| TW202415655A (en) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| WO2024019995A1 (en) * | 2022-07-19 | 2024-01-25 | Dana-Farber Cancer Institute, Inc. | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
| WO2024193464A1 (en) * | 2023-03-17 | 2024-09-26 | 西藏海思科制药有限公司 | Nitrogen-containing tricyclic derivative and use thereof in medicine |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
| CA2244897C (en) | 1996-03-05 | 2006-04-11 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PL205557B1 (en) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | New intermediate compounds and methods of their production |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (en) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
| IL153325A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| KR20030014425A (en) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | Colchinol derivatives as vascular damaging agents |
| UY27304A1 (en) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | INHIBITORS OF THE INHIBITOR FACTOR OF MIGRATION OF MACROPHAGES AND METHODS FOR IDENTIFICATION |
| CN102245612B (en) * | 2008-11-11 | 2014-11-05 | 第一药品株式会社 | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| MX2015010983A (en) | 2013-03-05 | 2015-10-26 | Hoffmann La Roche | Inhibitors of bruton's tyrosine kinase. |
| US9943506B2 (en) | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| JP6999688B2 (en) * | 2016-12-13 | 2022-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel 6-aminoquinolinone compounds and derivatives as BCL6 inhibitors |
| CN118561812A (en) | 2017-05-26 | 2024-08-30 | 癌症研究科技有限公司 | Benzimidazolone-derived BCL6 inhibitors |
| EP4371562A3 (en) * | 2017-05-26 | 2024-08-14 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| SG11202009735QA (en) * | 2018-04-13 | 2020-10-29 | Cancer Research Tech Ltd | Bcl6 inhibitors |
-
2019
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en active Application Filing
- 2019-04-12 KR KR1020207032149A patent/KR20200144109A/en not_active Application Discontinuation
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/en unknown
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/en active Active
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
- 2019-04-12 IL IL296734A patent/IL296734A/en unknown
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/en unknown
- 2019-04-12 ES ES19718834T patent/ES2939776T3/en active Active
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/en unknown
- 2019-04-12 PT PT197188345T patent/PT3774817T/en unknown
- 2019-04-12 CN CN201980039513.4A patent/CN112334475B/en active Active
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 EP EP22211485.2A patent/EP4201939A1/en active Pending
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/en active
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/en unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US20230287003A1/en active Pending
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501A1/en active Pending
-
2024
- 2024-05-21 JP JP2024082277A patent/JP2024119835A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20230120T1 (en) | 2023-06-09 |
| US20230287003A1 (en) | 2023-09-14 |
| CN112334475A (en) | 2021-02-05 |
| IL277778B (en) | 2022-11-01 |
| CN112334475B (en) | 2024-10-29 |
| AU2019253510B2 (en) | 2023-08-10 |
| EP3774817B1 (en) | 2022-12-07 |
| CA3095371A1 (en) | 2019-10-17 |
| PT3774817T (en) | 2023-03-09 |
| US20210163497A1 (en) | 2021-06-03 |
| JP2024119835A (en) | 2024-09-03 |
| EP3774817A1 (en) | 2021-02-17 |
| IL277778B2 (en) | 2023-03-01 |
| IL296734A (en) | 2022-11-01 |
| JP7493454B2 (en) | 2024-05-31 |
| JP2021521165A (en) | 2021-08-26 |
| EP4201939A1 (en) | 2023-06-28 |
| DK3774817T3 (en) | 2023-02-13 |
| AU2019253510A1 (en) | 2020-10-22 |
| IL277778A (en) | 2020-11-30 |
| MX2023004920A (en) | 2023-05-16 |
| ES2939776T3 (en) | 2023-04-26 |
| MX2020010805A (en) | 2021-01-29 |
| AU2023263501A1 (en) | 2023-11-30 |
| KR20200144109A (en) | 2020-12-28 |
| BR112020020832A2 (en) | 2021-01-19 |
| US11512095B2 (en) | 2022-11-29 |
| WO2019197842A1 (en) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| IL292642A (en) | Ras inhibitors | |
| IL292643A (en) | Ras inhibitors | |
| IL292644A (en) | Ras inhibitors | |
| IL269196A (en) | Novel inhibitors | |
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| IL277778B (en) | Bcl6 inhibitors | |
| IL276813A (en) | Arginase inhibitors | |
| EP3817736A4 (en) | Pikfyve inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| GB201819126D0 (en) | Inhibitor compounds | |
| ZA201808552B (en) | Novel b-lactamase inhibitors | |
| EP3600301A4 (en) | Kdm4 inhibitors | |
| IL283309A (en) | Rip1 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL277806A (en) | Growth inhibitor | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| IL283112A (en) | Lox inhibitors | |
| GB201809295D0 (en) | Lox inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor |